CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE
Clinical trials for CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE explained in plain language.
Never miss a new study
Get alerted when new CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE trials appear
Sign up with your email to follow new studies for CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug combo free CML patients from daily pills?
Disease control Recruiting nowThis study is for adults with chronic myeloid leukemia (CML) who have been on standard therapy for at least 5 years but were unable to stop treatment in the past. Researchers want to see if adding a newer drug called asciminib to their current medication can help them achieve a s…
Matched conditions: CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE
Phase: PHASE2 • Sponsor: Korean Society of Hematology • Aim: Disease control
Last updated May 17, 2026 06:18 UTC
-
New combo strategy aims to deepen remission in CML
Disease control Recruiting nowThis study tests a new drug, asciminib, as the first treatment for adults newly diagnosed with chronic myeloid leukemia (CML). If the drug alone doesn't work well enough after 2-3 years, a low dose of another standard drug is added. The goal is to see if this approach can achieve…
Matched conditions: CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE
Phase: PHASE2 • Sponsor: Augusta University • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New pill aims to control leukemia when other drugs fail
Disease control Recruiting nowThis study tests a new daily pill, TERN-701, for people with chronic myeloid leukemia (CML) whose current treatments are not working well or cause side effects. About 180 adults will take the pill once a day to see if it is safe and can control their cancer. The goal is to find t…
Matched conditions: CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE
Phase: PHASE1, PHASE2 • Sponsor: Terns, Inc. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC